-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Downgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $42

Benzinga·04/20/2026 15:55:28
Listen to the news
Wells Fargo analyst Benjamin Burnett downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Overweight to Equal-Weight and raises the price target from $35 to $42.